Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 361

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 361
---
 the Merger Agreement, including the exceptions to the events                                                                              
 that would constitute a Material Adverse Effect on Kineta for purposes of the Merger Agreement, as well as the likelihood of satisfaction of all conditions to completion of the transactions; |

| • |     | the ability of Kineta stockholders to approve or reject the Mergers by voting on the adoption of the Merger 
 Agreement;                                                                                                  |

| • |     | the requirement to not acquire or dispose of assets or otherwise taking any other action that would limit                                                                                             
 Kineta’s or TuHURA’s freedom of action, except for a Permitted Asset Disposition, the disposition of the Non-VISTA Assets or the disposition or dissolution of Kineta Chronic Pain, LLC, a Washington 
 limited liability company;                                                                                                                                                                            |

| • |     | the fact that the Kineta Board of Directors has the right, after complying with specified covenants and prior to                                                                                                                                          
 the Kineta stockholder approval being obtained, to change its recommendation to the Kineta stockholders that they vote in favor of the adoption of the Merger Agreement if the Kineta Board of Directors determines in good faith after consultation with 
 Kineta’s outside legal counsel and financial advisors, that as a result of a Superior Proposal or certain intervening events the failure to change its recommendation would be inconsistent with its fiduciary duties to Kineta’s stockholders            
 under applicable Delaware law;                                                                                                                                                                                                                            |

| • |     | the requirement that, in the event of the termination of the Merger Agreement under certain circumstances, TuHURA 
 will pay Kineta a termination fee of $1,000,000; and                                                              |

| • |     | Kineta’s right to terminate the Merger Agreement under certain circumstances, including in order to accept                                                                                                                                                
 and enter into a definitive agreement with respect to an unsolicited Superior Proposal in certain circumstances, subject to providing TuHURA an opportunity to match such offer prior to taking such action and payment to TuHURA of a termination fee of 
 $1,000,000 if the Merger Agreement is so terminated, which amount the Kineta Board of Directors believes to be reasonable under the circumstances, taking into account the range of such termination fees in similar transactions.                        |

With respect to the agreements related to the Asset Sales:

| • |     | the reasonableness of the nature of the liabilities to be assumed by each of HCRX, Pacira and GigaGen following 
 consummation of the Asset Sales;                                                                                |

227

|